The investigators built IBDex from 3,168 intestinal biopsies collected from 1,680 patients with Crohn’s disease, ulcerative colitis or no IBD. These biopsies were drawn from four cohorts and public repositories; the source material and cohort lists are provided by the authors. Patients were partitioned so each remained in a single training, validation or test fold during model construction. The authors supplied reference coordinates, pathway scores and axis scores for all construction biopsies with the released package, along with per-gene standardization and clipping statistics.
The study team trained a tissue-aware conditional variational autoencoder on a 3,000-gene interface. The training included adversarial suppression of cohort identity to reduce dataset-specific signals. After training, the investigators froze the scaling, encoder, decoder, pathway basis and phenotype direction parameters so new cohorts could be analyzed without retraining the model. The frozen design is meant to let downstream users transfer a consistent molecular scale across independent bulk transcriptomic studies.
The authors applied phenotype-anchored counterfactual perturbation (PACP) to produce anatomy-conditioned gene-response maps. PACP provided a mechanism to perturb phenotype directions on the frozen atlas and observe gene-level responses conditioned on tissue anatomy. Data indicated PACP could disambiguate overlapping signals that confounded marginal differential expression analyses, enabling clearer attribution to inflammation or to disease-state biology.
When tested without parameter updates on held-out data, dataset identity prediction fell near chance levels (balanced accuracy 0.307 vs 0.250), indicating successful suppression of cohort-specific signatures. At the same time, anatomy, diagnosis and inflammation signals remained recoverable from the frozen coordinates — inflammation classification reached an AUC of 0.82. The study team reported that marginal differential expression conflated inflammation and disease state (rho = 0.834), while PACP-separated response maps reversed that correlation (rho = -0.161).
The authors examined 93 patients who were in combined endoscopic and histological remission. In those patients, inflammation signatures moved toward control levels (AUC 0.58), suggesting return of inflammatory signals toward baseline. Disease-state-associated signatures, however, remained displaced (AUC 0.725), and the report provides a statistical comparison with P = 1.8 x 10^-10. In other words, the frozen atlas differentiated clinical remission from persistent molecular disease state, with inflammation and disease-state programs tracking differently.
The frozen atlas was applied to three unseen IBD cohorts and to a longitudinal olamkicept therapy trial without updating parameters. The investigators observed that the atlas recovered clinical structure, single-cell-defined signatures and disease-behavior patterns in these external datasets. During olamkicept therapy, the frozen reference tracked responder trajectories. The model also discriminated cohorts with primary sclerosing cholangitis (PSC) at the patient level (AUC 0.794) and colorectal cancer (CRC) with reported AUCs between 0.938 and 1.000.
The authors noted situations in which de novo differential expression became unreliable when applied cohort-by-cohort. In those cases, transferred PACP response maps remained reproducible, with reported correlation coefficients rho ≥ 0.89 for reproduced maps. This suggests that the frozen atlas can provide stable gene-response estimates even when standard differential testing is inconsistent across datasets.
All construction cohorts are public and named by the authors; the paper lists GEO and ArrayExpress accession IDs and other public resources used. The authors distributed the frozen panel membership, reference coordinates, pathway and axis scores, and per-gene standardization/clipping statistics with the released package available from the project site. The manuscript is a preprint and has not been peer reviewed; the authors explicitly state that it should not be used to guide clinical practice. The source did not report additional experimental or cohort-level methodological details beyond those summarized here. Remaining open questions recorded by the authors include how the frozen atlas performs across other untested tissue preparation protocols and whether prospective clinical deployment requires further validation in randomized or interventional studies.